269 related articles for article (PubMed ID: 26070816)
1. Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Lee WR; Shen SC; Shih YH; Chou CL; Tseng JT; Chin SY; Liu KH; Chen YC; Jiang MC
J Transl Med; 2015 Jun; 13():191. PubMed ID: 26070816
[TBL] [Abstract][Full Text] [Related]
2. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
[TBL] [Abstract][Full Text] [Related]
3. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
Elsner A; Lange F; Fitzner B; Heuschkel M; Krause BJ; Jaster R
World J Gastroenterol; 2014 Jun; 20(24):7914-25. PubMed ID: 24976727
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
[TBL] [Abstract][Full Text] [Related]
6. CSE1L Links cAMP/PKA and Ras/ERK pathways and regulates the expressions and phosphorylations of ERK1/2, CREB, and MITF in melanoma cells.
Lee WR; Shen SC; Wu PR; Chou CL; Shih YH; Yeh CM; Yeh KT; Jiang MC
Mol Carcinog; 2016 Nov; 55(11):1542-1552. PubMed ID: 26331446
[TBL] [Abstract][Full Text] [Related]
7. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.
Chin SY; Wu PR; Shih YH; Yeh CM; Lee WR; Shen SC; Yeh KT; Jiang MC; Tseng JT
Int J Clin Exp Pathol; 2015; 8(2):1393-401. PubMed ID: 25973023
[TBL] [Abstract][Full Text] [Related]
8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
9. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Carlo-Stella C; Locatelli SL; Giacomini A; Cleris L; Saba E; Righi M; Guidetti A; Gianni AM
PLoS One; 2013; 8(4):e61603. PubMed ID: 23620775
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
12. Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Sanderson L; Yardley V; Croft SL
J Antimicrob Chemother; 2014 Jul; 69(7):1888-91. PubMed ID: 24668412
[TBL] [Abstract][Full Text] [Related]
13. Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
Laurila JP; Laukkanen MO; Joensuu H; Salmi M; Jalkanen S
Int J Cancer; 2016 Nov; 139(10):2270-6. PubMed ID: 27459381
[TBL] [Abstract][Full Text] [Related]
14. Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
Wehler TC; Hamdi S; Maderer A; Graf C; Gockel I; Schmidtmann I; Hainz M; Berger MR; Theobald M; Galle PR; Moehler M; Schimanski CC
Int J Colorectal Dis; 2013 Mar; 28(3):385-98. PubMed ID: 22983756
[TBL] [Abstract][Full Text] [Related]
15. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
Botton T; Yeh I; Nelson T; Vemula SS; Sparatta A; Garrido MC; Allegra M; Rocchi S; Bahadoran P; McCalmont TH; LeBoit PE; Burton EA; Bollag G; Ballotti R; Bastian BC
Pigment Cell Melanoma Res; 2013 Nov; 26(6):845-51. PubMed ID: 23890088
[TBL] [Abstract][Full Text] [Related]
16. CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells.
Liao CF; Lin SH; Chen HC; Tai CJ; Chang CC; Li LT; Yeh CM; Yeh KT; Chen YC; Hsu TH; Shen SC; Lee WR; Chiou JF; Luo SF; Jiang MC
Mol Med; 2012 Dec; 18(1):1269-80. PubMed ID: 22952058
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
Voce P; D'Agostino M; Moretti S; Sponziello M; Rhoden K; Calcinaro F; Tamburrano G; Tallini G; Puxeddu E; Filetti S; Russo D; Durante C
Oncol Rep; 2011 Nov; 26(5):1075-80. PubMed ID: 21850379
[TBL] [Abstract][Full Text] [Related]
19. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
20. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
